Calcium2026-06

[Osteodystrophy in chronic liver disease].

Eiken Pia, Al-Omran Atheer Adel, Schiødt Frank Vinholt — Ugeskrift for laeger

Summary

Hepatic osteodystrophy is a bone condition that can affect people with long-term liver disease, leading to weakened bones and fractures. If you have chronic liver disease and are over 50, especially if you've had fractures, early screening for osteoporosis is recommended. Treatments involve calcium, vitamin D, lifestyle changes, and medications like bisphosphonates or denosumab to improve bone density.

AI-generated summary — read the original

Abstract

Hepatic osteodystrophy is defined as a metabolic bone disease that may occur in individuals with chronic liver disease (CLD). Hepatic osteodystrophy commonly manifests with osteoporosis and fragility fractures. This review finds that patients older than 50 years with CLD should be screened for possible osteoporosis earlier if they experience fragility fractures. Treatment includes calcium, vitamin D, and lifestyle interventions. Bisphosphonates, such as alendronate, and denosumab increase bone mineral density in CLD patients.

View on PubMed →DOI: 10.61409/V12230769